Compare Nuwellis Inc (NUWE) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs OneSpan Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while OneSpan Inc trades at $17.96 (market cap $662.97M). The key difference: OneSpan Inc is far larger — about 301.4× Nuwellis Inc's market cap, and OneSpan Inc pays a 2.89% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and OneSpan Inc for 18 Days on average.
| NUWE | OSPN | |
|---|---|---|
Market Cap | $2.20M | $662.97M |
Volume | 121,544 | 616,882 |
Sector | Health | Technology |
52-Week High | $146.65 | $18.42 |
52-Week Low | $0.68 | $10.15 |
Typical Hold Time | 26 Days | 18 Days |
Enterprise Value | -$1.52M | $632.05M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
OneSpan (OSPN) trades at $17.70, down 3.7% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 27.76% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and a new product launch, DigipassONE, aimed at authentication modernization.
The outlook remains positive given consistent earnings beats and a strong analyst buy consensus, though risks include negative net cash flow trends and competitive pressures in the technology sector. Revenue growth is modest, but high margins and a reasonable P/E of 10 support valuation. The stock presents a value opportunity with controlled risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
